New Organic Hemp Products Target Emerging Market
December 27 2018 - 2:01PM
InvestorsHub NewsWire
![](https://investorshub.advfn.com/uimage/uploads/2018/12/6/kaqsyRelevium_-_Capture.PNG)
Montreal, QC -- December 27, 2018 -- InvestorsHub NewsWire
-- Relevium Technologies Inc. TSX.V:"RLV", OTCQB: "RLLVF" and Frankfurt:
"6BX")
By Jeff Nielson, Stockhouse
By now, hemp is clearly on the radar of cannabis investors – for
several reasons. First, the hemp sub-species of cannabis actually
has many more commercial/industrial applications than the marijuana
sub-species.
Second, as cannabis laws are normalized around the world, hemp is
already legal (and available to be commercialized) in many more
markets than marijuana, for a very important reason. Hemp contains
negligible levels of THC, the cannabinoid in marijuana that
produces mild psychoactive effects.
However, hemp is especially rich in cannabidiol (CBD),
leading to the third reason that cannabis investors are becoming
more and more interested in hemp: the dramatic surge in consumer
and investor interest in products containing CBD. One Company that
is moving to capitalize on these opportunities is Relevium
Technologies Inc. (TSX: RLV, OTCQB: RLLVF).
Relevium is now familiar to the Stockhouse audience, having been
covered in several previous feature articles. For cannabis
investors who are new to RLV, they may want to check out recent coverage of the launch of
Relevium’s nutraceutical distribution deal with
Walmart.
![](https://investorshub.advfn.com/uimage/uploads/2018/12/27/pbeqeCapture._-_Relevium_LL_PNG.PNG)
Now the Company has more news. On December 13, 2018; RLV announced
the launching of its Leefylyfe™ brand of organically
sourced “full spectrum” hemp CBD products in the UK – on a
pre-order basis. While hemp is on the radar of cannabis investors,
the UK market for cannabis probably is not.
This is because the UK is an emerging cannabis jurisdiction. On
November 1, 2018; medicinal cannabis use became
officially legal in the United Kingdom. Relevium is wasting no time
in jumping into this market. With its population of 66.5 million
people, the UK is now one of the single largest markets for
medicinal cannabis in the world.
RLV’s organic hemp CBD nutraceuticals are perfectly timed to enter
this market as the people of this nation (for the first time) look
to obtain the known health benefits from cannabinoid consumption,
most specifically, cannabidiol. Several exclusive formulations of
Leefylyfe™ are planned for launch in 2019, with the Company also
targeting additional EU markets to extend Leefylyfe™ sales.
Opening up further possibilities for Leefylyfe™ products is the
pending passage of the U.S. Farm Bill 2018, which includes a
provision to legalize hemp for commercial purposes within the
United States, at the national level.
Relevium’s Chief Marketing Officer, Abis Hussein put this news into
a strategic context for investors.
The launch of LeefyLyfe™ is consistent with our focus
on creating new revenue streams, diversifying the
product offering and continuing to elevate our trusted brands. The
company is actively integrating Phyto-cannabinoids into its OTC
business to provide bring the natural goodness of Hemp to its
portfolio and trusted Health and Wellness products.
Leefylyfe™ products are produced by a local supplier in Europre.
BGX E-Health LLC, Relevium’s wholly-owned subsidiary based in
Orlando, Florida, is currently testing a complete line of dietary
supplements derived from cannabis, with an initial focus on
hemp.
BGX E-Health is also the producer of RLV’s “Bioganix®” brand
portfolio, which includes dietary supplements, nutraceuticals,
sports nutrition and cosmeceuticals. Relevium’s brands are already
available from some of the world’s largest retailers, including
Amazon.com and Walmart.com.
Aurelio Useche, CEO of Relevium shared these additional
insights.
The entire Relevium team is proud and excited to launch
LeefyLyfe™ on a pre-order basis. Our product strategy is to source
locally in Europe, from GMP and Certified Organic producers, a Hemp
product that is natural and rich in cannabinoids while
respecting the THC threshold that is legally acceptable in the
region. [emphasis mine]
It is this last factor that gives hemp-derived CBD products a
regulatory (and marketing) advantage as Relevium looks to extend
distribution of Leefylyfe™ across Europe. Several EU jurisdictions
still have extremely strict import and consumer restrictions on any
cannabis products with significant THC content.
By sourcing its CBD from organic hemp, Relevium can be an early
mover in many of these jurisdictions, as Europe catches up to North
America as a market for cannabis products. As a trusted producer of
nutraceutical products, and through sourcing its CBD products from
organic hemp, the Company is confident that it can achieve broad
market penetration with its new Leefylyfe™ product line.
Globally, the market for dietary health supplements is projected to
soar to over $278 billion by 2024. CBD-based
nutraceuticals have obvious potential to claim a significant share
of this market. As investors look to capitalize on opportunities in
this space, Relevium Technologies is turning heads with both its
development of distribution channels and new product offerings.
releviumtechnologies.com
FULL DISCLOSURE: This is a paid article of Stockhouse
Publishing.
Relevium Technologies (CE) (USOTC:RLLVF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Relevium Technologies (CE) (USOTC:RLLVF)
Historical Stock Chart
From Aug 2023 to Aug 2024